調査レポートカテゴリー： Infiniti Research TechNavio, 北米, 医療/バイオ

HER-2 Positive Breast Cancer Market in the US 2015-2019

米国のHER2陽性乳がん治療市場2015-2019

◆タイトル：HER-2 Positive Breast Cancer Market in the US 2015-2019
◆商品コード：IRTNTR5344
◆調査・発行会社：Technavio (Infiniti Research Ltd.)
◆発行日：2015年3月18日
◆ページ数：108
◆資料形式：pdf / 英語
◆納品方法：Eメール
◆調査対象地域：米国
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD3,000 ⇒換算￥327,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算￥381,500見積依頼/購入/質問フォーム
Enterprise License（全社内共有可）USD4,500 ⇒換算￥490,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

 【資料の概要】

当調査レポートでは、米国のHER2陽性乳がん治療市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国のHER2陽性乳がん治療市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。

About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio’s analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

[Other Prominent Vendors]
• Bristol-Myers Squibb
• DARA BioSciences
• Eisai
• Hospira
• Pfizer
• ProStrakan
• Sun Pharmaceutical Industries
• Teva Pharmaceutical

[Market Driver]
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report

[Market Challenge]
• Poor Diagnosis and Screening
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 IHC
06.4.2 FISH
06.4.3 SPoT-Light HER-2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER-2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Type of Therapy
08.1 Chemotherapy
08.1.1 Alkylating Agents
08.1.2 Antimetabolites
08.1.3 Cytotoxic Antibiotics
08.1.4 Taxanes
08.2 Targeted Therapy
08.3 Hormone Therapy

09.9 Market Segmentation by Molecule Type
09.1 Biologics
09.2 Small Molecules

10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11 Buying Criteria

12 Market Growth Drivers

13 Drivers and their Impact

14 Market Challenges

15 Impact of Drivers and Challenges

16 Market Trends

17 Trends and their Impact

18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of the Top Drugs
18.2.2 Celgene
18.2.3 F. Hoffmann-La Roche
18.2.4 GlaxoSmithKline
18.2.5 Novartis
18.2.6 Sanofi
18.3 Other Prominent Vendors

19 Key Vendor Analysis
19.1 Celgene
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Business Segmentation by Revenue
19.1.5 Sales by Geography
19.1.6 Key Information
19.1.7 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis

20 Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Pathophysiology of HER-2 Positive Breast Cancer
Exhibit 3: Prevalence of HER-2 Positive Breast Cancer in US 2014
Exhibit 4: Prevalence of HER-2 Positive Breast Cancer in US 2014 (in percentage)
Exhibit 5: IHC: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 6: FISH: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines for HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of HER-2 Positive Breast Cancer Market in US
Exhibit 10: Snapshot of HER-2 Positive Breast Cancer Market in US 2014
Exhibit 11: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 12: Drivers and Challenges of HER-2 Positive Breast Cancer Market in US
Exhibit 13: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy
Exhibit 14: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy 2014
Exhibit 15: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type
Exhibit 16: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type 2014
Exhibit 17: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration
Exhibit 18: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration 2014
Exhibit 19: Buying Criteria of HER-2 Positive Breast Cancer Market in US
Exhibit 20: Drivers and their Impact on Key Customer Category of HER-2 Positive Breast Cancer Market in US
Exhibit 21: Five-year Survival Rate by Stage of Diagnosis (SEER Analysis for 2004-2010)
Exhibit 22: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer 2013 (US$ million)
Exhibit 23: Celgene: Product Portfolio
Exhibit 24: Abraxane: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 25: F. Hoffmann-La Roche: Product Portfolio
Exhibit 26: Herceptin: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 27: Perjeta: Revenue 2012 and 2013 (US$ million)
Exhibit 28: Xeloda: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 29: GlaxoSmithKline: Product Portfolio
Exhibit 30: Tykerb: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 31: Novartis: Product Portfolio
Exhibit 32: Femara: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 33: Sanofi: Product Portfolio
Exhibit 34: Taxotere: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 35: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: Celgene: Sales by Geography 2013
Exhibit 37: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 38: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
Exhibit 44: GlaxoSmithKline: Pipeline Products 2013
Exhibit 45: Novartis AG: Business Segmentation
Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 49: Sanofi SA: Business Segmentation
Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013



【掲載企業】

Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Bristol-Myers Squibb , DARA BioSciences, Eisai , Hospira , Pfizer , ProStrakan, Sun Pharmaceutical Industries , Teva Pharmaceutical

【資料のキーワード】

米国、HER2陽性乳がん、治療、化学療法、治療薬

★調査レポート[米国のHER2陽性乳がん治療市場2015-2019] (HER-2 Positive Breast Cancer Market in the US 2015-2019 / IRTNTR5344)販売に関する免責事項
[米国のHER2陽性乳がん治療市場2015-2019] (HER-2 Positive Breast Cancer Market in the US 2015-2019 / IRTNTR5344)についてEメールでお問い合わせ
◆関連調査資料◆
  • 癌性疼痛治療薬の世界市場2015-2019
    IRTNTR7585 / Technavio / 2016年1月20日 / 当調査レポートでは、癌性疼痛治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、癌性疼痛治療薬の世界市場規模及び予測、種類別分析、地域別分析/市場規模、パイプライン分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Cancer Pain Therapeutics Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain. Technavio’s analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020. [Covered in this report]...
  • HER2陰性乳癌治療薬の世界市場2015-2019
    IRTNTR7383 / Technavio / 2015年9月30日 / 当調査レポートでは、HER2陰性乳癌治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、HER2陰性乳癌治療薬の世界市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About HER2-negative breast cancer HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a...
  • 子宮頸がん治療薬の世界市場2015-2019
    IRTNTR7066 / Technavio / 2015年9月9日 / 当調査レポートでは、子宮頸がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、子宮頸がん治療薬の世界市場規模及び予測、種類別分析、用途別分析、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About cervical cancer Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and...
  • 密封小線源療法用医療機器の世界市場2015-2019
    IRTNTR6738 / Technavio / 2015年7月29日 / 当調査レポートでは、密封小線源療法用医療機器の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、密封小線源療法用医療機器の世界市場規模及び予測、種類別分析、製品別分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Brachytherapy Devices Radiation therapy uses ionizing radiation to treat cancer. It comprises internal radiation therapy (brachytherapy) and external radiation therapy. In brachytherapy, radioactive material is placed near or next to the tumor. It uses higher doses of radiation to treat a small area. It is suitable for smaller and early-stage tumours, and is used in the treatment of various cancers, including gynaecological and prostate cancer. Brachytherapy can also be combined with other radiation therapies to treat cancer. The radioactive materials used for brachytherapy include: cesium, gold, iodine, iridium, and palladium. Technavio’s analysts forecast the global brachytherapy devices market to...
  • 腎臓がん治療薬の世界市場2015-2019
    IRTNTR6298 / Technavio / 2015年7月1日 / 当調査レポートでは、腎臓がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、腎臓がん治療薬の世界市場規模及び予測、製品パイプライン分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Kidney Cancer Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders. Kidney cancer can be triggered by a number of factors including both lifestyle-related...
  • 大腸癌治療薬の世界市場2015-2019
    IRTNTR6118 / Technavio / 2015年6月17日 / 当調査レポートでは、大腸癌治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、大腸癌治療薬の世界市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、地域別分析、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Colorectal Cancer Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in...
  • 小細胞肺がん治療薬の世界市場2015-2019
    IRTNTR5579 / Technavio / 2015年3月18日 / 当調査レポートでは、小細胞肺がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、小細胞肺がん治療薬の世界市場規模及び予測、投与経路（ROA）別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Small Cell Lung Cancer Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell...
  • HER2陽性乳がん治療の世界市場：化学療法、標的治療、ホルモン療法
    IRTNTR5462 / Technavio / 2015年3月4日 / 当調査レポートでは、HER2陽性乳がん治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、HER2陽性乳がん治療の世界市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast...
  • 癌バイオマーカーの世界市場2015-2019
    IRTNTR5058 / Technavio / 2015年1月14日 / 当調査レポートでは、癌バイオマーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、癌バイオマーカーの世界市場規模及び予測、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Cancer Biomarkers Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker...
  • 米国の人工内耳市場2015-2019
    IRTNTR5042 / Technavio / 2015年1月14日 / 当調査レポートでは、米国の人工内耳市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国の人工内耳市場規模及び予測、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Cochlear Implants A cochlear implant is a surgically-implanted device that helps overcome complications in the inner ear or cochlea. The cochlea is a snail-shaped curled tube which is positioned in the area of the ear where nerves are present. A cochlear implant consists of two major components: An external component and an internal component. The external component includes a microphone, a speech processor (a computer), and a transmitter. The internal component includes a receiver/stimulator, and an electrode array. The sound processor receives sound waves and processes them into detailed digital information. The implant changes the digital information into electrical...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆